title: [The late results of the combined therapy of patients in 2nd-stage lymphogranulomatosis].
abstract: OBJECTIVE
  To define the scope of combined therapy according to prognostic factors in patients with Hodgkin's disease state II.
  
  
  METHODS
  98 patients with favorable and unfavorable Hodgkin's disease (HD) prognosis according to EORTC criteria (41 and 57 of group 1 and 2, respectively) entered the study. Unfavorable factors were: mixed HD variant and lymphoid depletion, ESR above 50 mm/h in stage A and 30 mm/h in stage B, involvement of more than 3 groups of lymph nodes, age over 40. Patients of group 1 received CVPP program: 2 courses before and after radiation of the primary disease zones in the total dose 40 Gy. Therapy of group 2 patients consisted of 3 CVPP courses before and 3 courses after irradiation of all the lymphatic collectors above the diaphragm in the total dose 35 Gy or radiation according to the extended program. Efficacy of therapy was assessed by EORTC criteria. The survival curves were calculated by Caplan and Meyer methods.
  
  
  RESULTS
  In groups 1 and 2 a complete a complete remission was achieved in 98 and 93%, 6-year survival was 100 and 91%, recurrence-free survival--94 and 87%, respectively. Survival free of the treatment failure reached in group 1--88%, in group 2--81%.
  
  
  CONCLUSIONS
  Reduced treatment in HD stage II in favourable prognosis did not worsen the results of treatment.
authors.forename: E A
authors.initials: EA
authors.lastname: Demina
authors.forename: T V
authors.initials: TV
authors.lastname: Iur'eva
authors.forename: G S
authors.initials: GS
authors.lastname: Tumian
authors.forename: N E
authors.initials: NE
authors.lastname: Konfrat'eva
authors.forename: N A
authors.initials: NA
authors.lastname: Pirogova
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors